# A First In Human Study Of PF-00184562 In Healthy Volunteers

> **NCT00150215** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 18 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** PF-00184562
- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT00150215
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 18 (—)
- **Last updated:** 2006-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00150215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00150215, "A First In Human Study Of PF-00184562 In Healthy Volunteers". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00150215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*